Hims & Hers Health stock drops more than 8% after persistent seller dominance and short-term resistance at 50-day moving average

Traders Union
All News
Stocks
Hims & hers slides 8.1% today

Highlights

Shares of Hims & Hers Health closed at $31.04, down 8.11%, after a downside gap of 5.27% and high intraday volatility.
The stock is trading above its 20-day and 200-day moving averages but remains below the 50-day, suggesting ongoing short-term resistance inside a longer-term bullish structure.
Forecast puts the 5-day expected range at $27.54 to $34.77, with 76% probability of an upward move and key breakout and breakdown levels at $32 and $30.05.

Anton Kharitonov, expert at Traders Union, notes the sharp sell-off and the persistent seller dominance in HIMS. He highlights that resistance at the 50-day moving average and overbought momentum readings clash with the broader uptrend. The absence of positive news flow and high intraday volatility are additional causes for caution. With the downside gap yet to be filled and multiple overbought signals, Kharitonov warns of elevated downside risk. He states, "I remain defensive on HIMS as the technical evidence points to ongoing pressure — unless strong buyers step in, a test of lower supports is likely."

Viktoras Karapetjanc, expert at Traders Union, sees the bullish medium- and long-term trend for HIMS as intact despite short-term resistance. He interprets the recent pullback as a temporary reaction and points to ongoing buyer momentum, reinforced by positive RSI and the alignment above key moving averages. Karapetjanc emphasizes further growth potential if the stock clears resistance at $32. He states, "With the bullish structure holding and buyers in control, I expect HIMS to resume its upward trajectory toward $34.77 if momentum sustains above $32."

Parshwa Turakhiya, analyst, observes that HIMS offers a blend of high volatility and mixed momentum signals. He notes the overbought conditions flagged by Stochastic RSI and CCI, alongside a neutral short-term outlook. The sideways baseline scenario suggests limited directional conviction for now, but technical setups may appeal to agile traders. He comments, "With sellers active and volatility up, I see immediate trading opportunities around support at $30.05 and resistance at $32."

Short-term resistance holds as overbought signals diverge from pullback

The stock is trading above its 20-day moving average at $29.86 and 200-day moving average at $28.89, but remains slightly below the 50-day moving average at $32.03. This signals ongoing short-term resistance, with longer-term technical alignment still bullish. Immediate resistance stands at $32, anchored by today's low, while support is found at $30.05 at the Ichimoku Kijun line. The bullish structure between the 50-day and 200-day moving averages supports the medium- and long-term trend. Momentum indicators present a mixed picture: the MACD and ADX are neutral, the RSI at 58.13 signals a buy, but both the CCI at 163.05 and Stochastic RSI at 100 point to overbought conditions. Bull/Bear Power at 3.82 also signals an overbought market with buyers dominating, while the Awesome Oscillator is neutral. A downside gap of $1.78 (-5.27%) leaves the stock near today's low, with sellers exerting pressure and high intraday volatility at 7.47%. Overbought readings diverge from the ongoing session’s pullback.

Earlier, analysts noted that Hims & Hers Health maintained a bullish technical bias supported by a robust uptrend, though they cautioned that regulatory risks and overbought signals warranted close monitoring. The recent sharp pullback highlights the importance of watching support at $30.05, as a breakdown below this level could shift the technical outlook to the downside.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.